On Wednesday, April 25, BioMotiv colleagues and friends gathered to celebrate the opening of a new Philadelphia office located in The Innovation Hub, a collaborative life sciences space managed by Militia Hill Ventures. Based out of Cleveland, Ohio, BioMotiv is a mission-driven company that accelerates breakthrough discoveries from research institutions into therapeutics for patients. It is associated with The Harrington Project for Discovery & Development, a $340 million national initiative for advancing medicine centered at University Hospitals in Cleveland.
“Philadelphia is one of a very small, elite group of regions that offers extraordinary depth and breadth of combined academic research and pharmaceutical industry expertise,” said Baiju R. Shah, Chief Executive Officer of BioMotiv. “This new office will allow us to expand our presence and become a bigger part of the thriving biotech community in Philadelphia as we continue to advance a growing portfolio of drug development programs.”
“We look forward to having BioMotiv as a part of the network of biotech and life sciences resources and expertise in Philadelphia,” said Christopher P. Molineaux, President and Chief Executive Officer of Life Sciences Pennsylvania. “BioMotiv’s innovative business model will help foster the growth and success of life sciences in our region.”
BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $340 million national initiative for advancing medicine centered at University Hospitals in Cleveland, Ohio. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of drug development programs.